title: How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting.
abstract: BACKGROUND
  Evidence on sequential trial with atypical antipsychotics has been scarce.
  
  
  OBJECTIVE
  We conducted an algorithm-based antipsychotic pharmacotherapy.
  
  
  METHODS
  In this open-label study, patients with schizophrenia (DSM-IV) were treated with antipsychotic monotherapy, step-by-step, with each trial lasting up to 8 weeks. At baseline, they were highly symptomatic to score more than 54 in the total Brief Psychiatric Rating Scale (BPRS(1-7)) score. When the posttreatment BPRS score was above 70% of the baseline, they were subsequently treated with another and up to three atypicals. Basically, anticholinergics were prohibited, and only adjunctive allowed was lorazepam. The secondary endpoint was a clinical status good enough to be discharged for 66 inpatients and a successful continuation therapy with the same antipsychotic agent for more than 6 months for 12 outpatients.
  
  
  RESULTS
  Three groups of 26 patients each were randomized to Olanzapine, Quetiapine, or Risperidone. Thirty-nine (50%) responded to the first agent (Olanzapine16, Quetiapine9, Risperidone14), and 14 responded to the second. Only two showed response to the third, and 16 failed to respond to all three antipsychotics, with only 7 dropouts. Overall, there were 22 Olanzapine, 14 Quetiapine, and 19 Risperidone responders. Based on the secondary outcome, 20 Olanzapine-treated (average maximum dose, 15.4 mg), 10 Quetiapine-treated (418 mg), and 20 Risperidone-treated (4.10 mg) patients responded. The difference in response as the first choice was significant (p < 0.05). Relative doses of those failing to respond were comparable (Olanzapine 18.3 mg, Quetiapine 564 mg, Risperidone5.47 mg). Extrapyramidal symptoms did not change significantly.
  
  
  CONCLUSIONS
  When the first atypical antipsychotic is inadequate, switching to the second is worth trying, although some remain treatment-refractory. Quetiapine may be inferior to Olanzapine and Risperidone in symptomatic patients.
authors: Department of Neuro-Psychiatry, School of Medicine, Keio University, 35, Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. takefumi@oak.dti.ne.jp
authors: Takefumi
authors: T
authors: Suzuki
authors: Hiroyuki
authors: H
authors: Uchida
authors: Koichiro
authors: K
authors: Watanabe
authors: Kensuke
authors: K
authors: Nomura
authors: Hiroyoshi
authors: H
authors: Takeuchi
authors: Masayuki
authors: M
authors: Tomita
authors: Kenichi
authors: K
authors: Tsunoda
authors: Shintaro
authors: S
authors: Nio
authors: Ryoske
authors: R
authors: Den
authors: Hiroshi
authors: H
authors: Manki
authors: Akira
authors: A
authors: Tanabe
authors: Gohei
authors: G
authors: Yagi
authors: Haruo
authors: H
authors: Kashima
mesh_terms: D000328:Adult; D000465:Algorithms; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003987:Dibenzothiazepines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077152:Olanzapine; D000069348:Quetiapine Fumarate; D018967:Risperidone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; D018967:Risperidone; D000077152:Olanzapine
references: J Clin Psychiatry. 2003;64 Suppl 12:2-97, quiz 98-100
references: 14640143
references: Clin Ther. 2005 Dec;27(12 ):1930-41
references: 16507379
references: Arch Gen Psychiatry. 1988 Sep;45(9):789-96
references: 3046553
references: Psychopharmacology (Berl). 2005 Dec;183(3):383-6
references: 16240162
references: Int Clin Psychopharmacol. 2006 Nov;21(6):369-72
references: 17012984
references: Schizophr Res. 2002 Oct 1;57(2-3):227-38
references: 12223254
references: J Clin Psychiatry. 2006 Jul;67(7):1093-103
references: 16889453
references: Aust N Z J Psychiatry. 2006 May;40(5):437-45
references: 16683970
references: Int Clin Psychopharmacol. 2003 Nov;18(6):323-9
references: 14571152
references: Can J Psychiatry. 1997 Feb;42(1):34-43
references: 9040921
references: Schizophr Bull. 2004;30(2):193-217
references: 15279040
references: Eur J Clin Pharmacol. 2004 Feb;59(12 ):905-9
references: 14685800
references: J Psychopharmacol. 2005 Sep;19(5 Suppl):32-8
references: 16144784
references: J Clin Psychiatry. 2005 Aug;66(8):1021-30
references: 16086618
references: Psychiatry Res. 2006 Nov 15;144(2-3):177-89
references: 17010448
references: Schizophr Bull. 2004;30(3):627-47
references: 15631256
references: Arch Gen Psychiatry. 2003 Jun;60(6):553-64
references: 12796218
references: J Clin Psychiatry. 2005 Dec;66(12 ):1564-8
references: 16401158
references: Am J Psychiatry. 2005 Mar;162(3):441-9
references: 15741458
references: Can J Psychiatry. 2005 Dec;50(14 ):901-8
references: 16494259
references: N Engl J Med. 2005 Sep 22;353(12 ):1209-23
references: 16172203
references: J Clin Pharm Ther. 2006 Feb;31(1):57-65
references: 16476121
references: Prog Neuropsychopharmacol Biol Psychiatry. 2004 Mar;28(2):361-9
references: 14751434
references: Psychopharmacology (Berl). 2005 Sep;181(3):566-75
references: 15991004
references: J Clin Psychopharmacol. 2006 Dec;26(6):571-8
references: 17110813
references: Neuropsychopharmacology. 2007 Sep;32(9):1903-10
references: 17287825
references: J Psychiatr Res. 2006 Oct;40(7):669-76
references: 16762371
references: J Clin Psychiatry. 2005 Dec;66(12):1512-6
references: 16401150
references: Int J Neuropsychopharmacol. 2006 Jun;9(3):357-66
references: 16316478
references: Schizophr Res. 2006 Sep;86(1-3):15-22
references: 16884895
references: J Clin Psychopharmacol. 2006 Oct;26(5):453-61
references: 16974184
references: Br J Psychiatry. 1980 May;136:413-20
references: 7388247
references: J Clin Psychiatry. 2004 Apr;65(4):500-8
references: 15119912
references: Br J Psychiatry. 2006 Nov;189:433-40
references: 17077434
references: J Clin Psychiatry. 2006 Sep;67(9):1391-6
references: 17017825
references: J Clin Psychopharmacol. 2006 Aug;26(4):401-4
references: 16855459
references: Am J Psychiatry. 2006 Apr;163(4):611-22
references: 16585435
references: Curr Med Chem. 2004 Feb;11(3):313-27
references: 14965234
references: Am J Psychiatry. 2006 Apr;163(4):600-10
references: 16585434
references: Int J Neuropsychopharmacol. 2004 Jun;7(2):133-42
references: 14741059
references: Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jul;29(6):972-82
references: 16023776
references: J Clin Psychopharmacol. 2006 Jun;26(3):238-49
references: 16702888
references: Int J Neuropsychopharmacol. 2005 Sep;8(3):457-72
references: 15784157
references: Can J Psychiatry. 2006 Jul;51(8):480-91
references: 16933585
references: BMJ. 2000 Dec 2;321(7273):1371-6
references: 11099280